Elranatamab

Overview

Elranatamab (PF-06863135) is a B-cell Maturation Antigen (BCMA)-CD3 bispecific antibody being tested in multiple myeloma.

SparkCures ID 302
Developed By Pfizer
Generic Name Elranatamab
Additional Names PF-06863135
Treatment Classifications
Treatment Targets

Clinical Trials

All Clinical Trials

View all active clinical trials around the US.

Early Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received one to two prior lines of therapy.

Late Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.

Smoldering Myeloma
Monoclonal Gammopathy of Undetermined Significance (MGUS)

Published Results

Higher Doses of Subcutaneous Elranatamab Show Efficacy in Relapsed/Refractory Myeloma

June 09, 2021

Doses at or above 215 μg/kg had the best outcomes, with an overall response rate (ORR) of 70% (n = 14). Out of the 215-, 360-, 600-, and 1000-μg/kg dose groups, the highest dose had the best outcomes, with an 83.3% ORR, including 16.7% of patients with a complete response, 50% with a very good complete response, and 16.7% with a partial response. Median time to response was 22 days, ranging from 21 to 50 days.

There were 14 patients with IMWG-confirmed response; in this cohort, median duration of response was not reached. There was a 92.3% probability (95% CI, 56.7-98.9) of responders being event-free at 6 months.

Within the entire study population, the most common all causality treatment-emergent adverse events (AEs) were

  • lymphopenia (83.3%; grade 3, 20% and grade 4, 60%),
  • cytokine release syndrome (CRS; 73%; all grade 1 and 2);
  • anemia (57%; grade 3, 43% and grade 4, 3%);
  • injection site reaction (53%; none above grade 2);
  • thrombocytopenia (53%; grade 3, 23% and grade 4, 17%);
  • and neutropenia (40%; grade 3, 17% and grade 4, 17%).

There were no dose-limiting toxicities.

Resources